Compare Heron Therapeutics Inc (HRTX) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Tripadvisor Inc Common Stock — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $68.01M), while Tripadvisor Inc Common Stock trades at $8.94 (market cap $1.01B). The key difference: Tripadvisor Inc Common Stock is far larger — about 14.9× Heron Therapeutics Inc's market cap, and Tripadvisor Inc Common Stock is more actively traded (3,004,748 versus 1,891,941). Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Tripadvisor Inc Common Stock for 57 Days on average.
| HRTX | TRIP | |
|---|---|---|
Market Cap | $68.01M | $1.01B |
Volume | 1,891,941 | 3,004,748 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.49 | $16.72 |
52-Week Low | $0.27 | $8.04 |
Typical Hold Time | 35 Days | 57 Days |
Enterprise Value | $174.75M | $1.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
TripAdvisor (TRIP) trades at $8.63, up 1.29% on the day but near its 52-week low of $8.27. The stock is technically bearish, with recent earnings misses and a net cash outflow of $29M in 2025. Revenue grew to $1.89B in 2025, but net margins remain thin at 0.27%. Analyst sentiment is mixed, with a consensus price target of $13.58 but a majority hold rating.
The outlook is cautious. Upside potential exists if the Viator segment recovers and TheFork sale concludes, but risks include persistent earnings volatility, competitive pressure from AI travel tools, and weak cash flow trends. The stock offers value on P/S (0.57) but requires improved execution to justify higher multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
